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Abstract: The increased interest in organoid research in recent years has contributed to an improved
understanding of diseases that are currently untreatable. Various organoids, including kidney, brain,
retina, liver, and spinal cord, have been successfully developed and serve as potential sources for
regenerative medicine studies. However, the application of organoids has been limited by their
lack of tissue components such as nerve and blood vessels that are essential to organ physiology.
In this study, we used three-dimensional co-culture methods to develop colonic organoids that
contained enteric nerves and blood vessels. The development of enteric nerves and blood vessels was
confirmed phenotypically and genetically by the use of immunofluorescent staining and Western
blotting. Colonic organoids that contain essential tissue components could serve as a useful model
for the study of colon diseases and help to overcome current bottlenecks in colon disease research.
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1. Introduction
Even though mice have been used as a disease model in biomedical fields, recent studies have
shown that mice do not reproduce the gene expression patterns that are induced by inflammatory
disease in humans. These studies have provoked a renewed discussion of the validity of animal
models in translational research [1,2]. Organoids are well-organized structures that include various
cell types from different developmental origins. Organoids containing structures found in whole
organs have been generated from pluripotent stem cells via the developmental stages by use of
three-dimensional (3D) culture systems [3]. An important advantage of organoids is that they display
similar characteristics and morphology to human organs [4]. Although extensive research has been
conducted on organoids, few studies exist of human colonic organoids (HCOs) [5,6]. The enteric
nervous system (ENS) is implicated in a broad range of intestinal and extra-intestinal disorders [7].
Similarly, blood vessels play an important role in many diseases [8,9]. However, despite the central
role of the ENS and blood vessels in intestinal function and health, our current understanding of their
role is incomplete because of long-standing technical challenges in the development of these structures
in organoid models [10].
Previously, Workman et al. described the methods for developing small intestine organoids
containing enteric nervous system (ENS) [11], and Kasendra et al. developed human small intestine
organoids from biopsy-derived stem cells [12]. For large intestine organoids, Múnera et al. developed
colonic organoids from human pluripotent stem cells via BMP signaling activation [13]. Although
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methods of HCO development have been established over recent years, their lack of other structures
such as nerves and blood vessels limits their applicability for the study of certain diseases such
as ulcerative colitis, Crohn’s disease, and Hirschsprung’s disease. Ulcerative colitis is a chronic
idiopathic inflammatory bowel disorder [14], and mucosal healing is a crucial factor for the treatment
of refractory inflammatory bowel disease patients [15]. Even though a previous study indicated
that endoscopy-assisted transplantation of intestinal stem cell plays as an emerging key role in the
treatment [15,16], colonic organoids are much more important because the majority of ulcerative colitis
lesions occurred in the rectum [17]. Moreover, transplantation of hematopoietic stem cells may improve
the treatment outcome [18,19]. Besides, Crohn’s disease is also an inflammatory gastrointestinal with
unknown etiology. However, in contrast to ulcerative colitis, this disease can affect both small and
large intestine. On the other hand, Hirschsprung disease is a birth defect caused by the absence of
neuronal ganglion nerve cells in different segments of bowel [20]. Previous study has engineered small
intestinal organoids with ENS for Hirschspurng’s disease study [11]. Nevertheless, it was reported
that 80% of patients had no neural ganglion in the rectosigmoid-segment and aganglionosis was rarely
observed in the small intestine [21]. Accordingly, we developed HCOs that contain well-characterized
enteric nerves or blood vessels, which is important for the investigation of colon diseases that involve
these structures. Additionally, these HCOs can be used as more realistic predictive and prognostic
models of colon diseases in humans.
2. Materials and Methods
2.1. Colonic Organoid Development Using Human Embryonic Stem Cells
Human embryonic stem cells (hESC) (SNUhes31 cell line) were obtained from Seoul National
University, Korea (Registration No. hES12010037) and incubated with 5% CO2 at 37 ◦C. The development
of HCOs was performed in three distinct phrases including gendoderm and hindgut differentiation
and colonic organoid development (Figure 1). Endoderm differentiation was performed in reference
to the previous study with some modifications [22]. On day 1, 200,000 human embryonic stem
cells (hESCs) were seeded in a 24-well plate and treated with B27 (1:100) (Gibco, Grand Island, NY,
USA, 12587-010), Activin A (100 ng/mL, Peprotech, Rock Hill, NJ, USA, 120-14E), and mesoderm
differentiation compound CHIR-99021 (3 µM, Sigma-Aldrich, St. Louis, MO, USA, SML1046-25MG),
in which B27 is the key component to improve cell survival in definitive endoderm. RPMI1640
(Welgene, Gyeongsan, Korea, LM01101) was used as the cell culture media. On day 2, cells were
treated with 0.2% fetal bovine serum (FBS) (Welgene, S001-07), Activin A (100 ng/mL), and CHIR-99021
(3 µM). On day 3, cells were treated with 2% FBS, Activin A (100 ng/mL), and CHIR-99021 (3 µM).
Hindgut differentiation was conducted according to Múnera et al. [13]. In brief, after 3 days
of endoderm differentiation, cells were cultured for 4 days in Dulbecco’s Modified Eagle’s Medium
(DMEM F/12) (Welgene, Gyeongsan, Korea, LM 002-04) supplemented with 2% FBS, fibroblast growth
factor 4 (FGF4) (100 ng/mL, Peprotech, Rock Hill, NJ, USA, 100-31), and CHIR-99021 (3 µM).
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Figure 1. Timeline for the development of enteric nervous syste (ENS) and blood vessel-containing
hu an colonic organoids (HCOs) from human embryonic stem cells (hESCs). The dashed line indicates
the 3D co-culture.
2.2. Development of Colonic Organoids Containing Enteric ervous Syste
Ectoder differentiation as based on the protocol described by Jasan Tc ie et al. ith so e
odifications [23]. In details, hESCs were cultured in DMEM F/12 ith 10 nockout Seru
replace ent ( SR) ( ibco, 10828-028). Ectoder differentiation co pounds, i cluding 193189
(500 ol, Sig a- ldrich, St. Louis, O, USA, SML0559), SB431542 (10 µ , Selleckchem, Houston,
, S , S1067), a I -99021 (3 µ ), ere a e f r 2 a s.
The e elo e t of HCOs containing enteric nerves was performed through treatment to promote
ectoderm an neural crest differentiation and hindgut co-culture. Development f HCOs in Matrigel
was performed according to previous study [13]. After 4 days of hindgut differentiation, Matrigel
(BD Science, Franklin Lakes, NJ, USA, 354234) was used to 3D culture the cells, supplemented with
BMP4 (10 ng/mL, R&D system, 314-BP-050), CHIR-99021 (3 µM), and EGF (500 ng/mL, Peprotech,
AF-100-15). The cells were cultured in DMEM F/12 with B27. The development of complete colonic
organoids required at least 28 days to 56 days in 3D culture.
eural crest was also differentiated in r f rence to the previous study [23] wit shorter time.
In bri f, ectoderm differentiated cells were cultured in DMEM F/12 medium supplemented ith
SB431542 (10 µ ) a I - ( µ ) f r s.
In or er t el c l ic r i c taining e teric ervous syste , differe tiated e ral
crest and hindgut co-culture as perfor ed on atrigel with BMP4 (10 ng/mL), CHIR- 9021 (3 µM),
and E F (500 ng/ L) for 3 days. CHIR- 9021 and EGF were then replaced by Sonic Hedgehog (SHH)
(20 g/ , r t c , - ) f r t r i r f t c -c lt r ri .
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2.3. Development of Colonic Organoids Containing Blood Vessels
Blood vessel development was performed according to previously described methods [24] with
some modifications including mesoderm differentiation, vascular lineage promotion, vascular networks,
and contact of the colon with vasculature. For mesoderm differentiation, hESCs were cultured for
2 days in DMEM F/12 with 20% KSR and CHIR-99021 (3 µM). Subsequently, for vascular lineage
promotion, mesoderm-differentiated cells were treated with BMP4 (10 ng/mL), FGF2 (30 ng/mL, Sigma,
SRP4037), and vascular endothelial growth factor A (VEGF-A) (30 ng/mL, Peprotech, 100-20) from day
3 to day 7. BMP4 was then replaced by SB31542 (10 µM) from day 8 to day 10. After that, cells were
treated with 15% FBS, FGF2 (30 ng/mL), and VEGF-A from day 10 to day 16 for vascular network
development. For the contact between the colon and vasculature, differentiated blood vessels were
co-cultured with hindgut on Matrigel on day 17. The culture was then treated with BMP4 (10 ng/mL),
EGF (500 ng/mL), CHIR-99021 (3 µM), and VEGF-A (30 ng/mL), FGF2 (30 ng/mL), then incubated until
day 28. After that, subcultures were performed every 10 days for 56 days.
2.4. Colon Cancer Organoid Development
The colon cancer cell line SW480 (lot No. 7772) was obtained from Seoul National University
(Seoul, Korea), and 3D culture was performed as described for HCO development.
2.5. Total RNA Extraction and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
Total RNA extraction was performed using Qiazol (Qiagen, Hilden, Germany), chloroform
(Duksan, Gyeonggi-do, Korea), and isopropanol (Sigma-Aldrich, St. Louis, MO, USA) according
to previously described methods [25]. cDNA was synthesized using a high-capacity cDNA reverse
transcription kit (Thermo Fisher, Waltham, MA, USA) according to the manufacturer’s instructions.
Quantitative real-time (qRT)-PCR was performed using the KAPA SYBR® FAST qPCR Master
Mix (Sigma-Aldrich, St. Louis, MO, USA). The primer sequences used in this study are listed
in Supplementary Materials, Table S1. All experiments were performed in technical triplicates.
2.6. Western Blotting
Western blotting was performed according to previously described methods, with some
modifications [26]. In brief, 20 µg of each organoid lysate was separated on a 10% SDS-PAGE
gel, then transferred onto a nitrocellulose membrane (GE Healthcare, Life Science, Chicago, IL, USA).
The nitrocellulose membranes were blocked with phosphate-buffered saline with Tween 20 (PBST)
buffer, then incubated overnight with primary antibody at 4 ◦C (Table S2). After washing, the membrane
was incubated with goat anti-mouse mouse IgG antibody (H + L) (1:1000, Thermo Fisher, 31430).
Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA, 170-5060) with X-ray film was used to
detect bands.
2.7. Hematoxylin & Eosin Staining
The organoids were removed from the gel state, then incubated overnight with 4% paraformaldehyde
(PFA) solution at 4 ◦C. The staining was performed in the histopathology room at the Yonsei University
College of Medicine (Seoul, Korea).
2.8. Immunofluorescent Staining
Immunofluorescent staining was performed according to previously described methods [13].
In brief, the organoids were slightly washed with 1X phosphate-buffered saline (PBS) solution, then
fixed with 4% PFA (Sigma-Aldrich, MO, USA) for at least 1 h.
Washing, permeabilization, and blocking were performed for 30 min with bis-tris propane (BTP)
buffer that included 0.5% bovine serum albumin (Genedepot, Katy, TX, USA, A0100-010) and 0.1%
Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) in PBS. The primary antibody (1:500 to 1:1000) was
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incubated with organoids overnight at 4 ◦C (Table S2). The next day, organoids were washed with
BTP buffer, then incubated with goat anti-mouse IgG (H + L) secondary antibody (1:1000, Thermo
Fisher, 31430). Organoids were washed again with BTP buffer for 30 min, then incubated in with
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, 1 µg/mL) for 10 min at room temperature in
dark. The organoids were observed on a fluorescence microscope after washing three times with 1X
PBS over a 30-min period.
2.9. Statistical Analysis
The changes in the expression level for each gene were calculated as described by Livak et al. [27].
For each sample, the threshold cycle (Ct) of the target gene was determined and normalized to the Ct
value of 18S rRNA and calculated relatively to the reference using the formula 2−∆∆Ct. The p values
were determined using t-test in Prism GraphPad version 8.1.1.
3. Results
3.1. Development and Characterization of Colonic Organoids
Previous studies indicate that endoderm formation is characterized by decreased expression of
pluripotency markers OCT4 and NANOG [28] and increased expression of endoderm differentiation
markers SOX17 and FOXA2 [29]. After 3 days of endoderm differentiation (Figure 2A,B), OCT4 and
NANOG expression levels were decreased in HCOs, compared with untreated hESCs. Conversely,
SOX17 and FOXA2 were highly expressed in HCOs, compared with untreated hESCs. The expression
of SOX17 and FOXA2 in HCOs was confirmed by Western blotting (Figure 2B).
Expression of KLF5 and CDX2 in hindgut differentiation has been previously demonstrated [30].
In the present study, after HCOs were treated with fibroblast growth factor 2 and CHIR99021 for
4 days, hindgut spheroids were observed on bright-field microscopy and on H&E staining. Increased
expression of KLF5 and CDX2 in HCOs, compared with untreated hESCs, was confirmed via qRT-PCR
and Western blotting (Figure 2C).
After at least 28 days of treatment with BMP4, CHIR-99021, and endothelial growth factor (EGF),
the HCO morphology was observed to include crypt-like structures (Figure 2D). The expression levels
of colon-specific marker (SATB2); posterior HOX markers (HOXA13, HOXB13, HOXD12, and HOXD13);
adult stem cell marker (LGR5); goblet cell markers (MUC2, MUC3, and MUC4); and markers for
paneth cells (DEFA5), enteroendocrine cells (CHGA), and enterocytes (villin), as detected by qRT-PCR,
were increased in HCOs, compared with that in untreated hESCs (Figure 2D). This differential
expression between HCOs and untreated hESCs was consistent with the results of a previous study [31].
The increased expression of SATB2, LGR5, MUC4, DEFA5, CHGA, and villin in HCOs was confirmed
by Western blotting (Figure 2D) and immunofluorescent staining (Figure 2E). Furthermore, spherical
hollow structures within the colon epithelium of HCOs were visible on H&E staining (Figure 2E).
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Figure 2. Development and characterization of HCOs. (A) HCO differentiation protocol. (B) Expression
of pluripotency markers (OCT4 and NANOG) and endoderm differentiation markers (SOX17 and
FOXA2) in the definitive endoderm (DE) of HCOs and untreated hESCs as detected via qRT-PCR.
SOX17 and FOXA2 expression was detected by Western blotting, with GAPDH used as a loading control.
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(C) Hindgut (HG) morphology on bright-field (BF) microscopy and H&E staining. Expression of
hindgut markers (CDX2 and KLF5) as detected via qRT-PCR. (D) Development of morphologic changes
in HCOs over time. Crypt-like structures had formed by day 28. Expression of colon-specific marker
(SATB2); posterior HOX markers (HOXA13, HOXB13, HOXD12, and HOXD13); adult stem cell marker
(LGR5); goblet cell markers (MUC2, MUC3, and MUC4); and markers for paneth cells (DEFA5),
enteroendocrine cells (CHGA), and enterocytes (villin) by HCOs as detected via qRT-PCR. Detection
of SATB2, LGR5, MUC4, DEFA5, CHGA, and villin by Western blotting, with GAPDH used as the
loading control. The scale bars in panels (a–e) indicate 200 µm; the scale bar in panel (f) indicates
100 µm. (E): H&E and immunofluorescent staining of HCOs. The scale bar in panel (a) indicates
200 µm; the scale bar in panel (b) indicates 50 µm. * p ≤ 0.1, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001.
Scale bar: 200 µm.
The expression of markers and cells in colon cancer organoids (CCO) from colon cancer cell lines
differed from that in HCOs (Figure S1). Compared with HCOs, the expression of MUC4 and villin in
CCOs was decreased, whereas there was no difference in the expression of DEFA5 or CHGA between
CCOs and HCOs.
3.2. Development of Colonic Organoids Containing Enteric Nervous System
Previous studies indicate that Nestin and OTX2 are ectoderm differentiation markers [32],
and SOX10, and FOXD3 are markers for neural crest differentiation [33]. In addition, the expression
of ectoderm and neural crest inhibitors such as NANOG and OCT4 are reduced [34]. After 2 days
of treatment with LDN193189, SB431542, and CHIR99021, there was a decrease in the expression of
NANOG and OCT4, and the expression levels of Nestin and OTX2 were increased in HCOs, compared
with untreated hESCs (Figure 3A). The expression levels of SOX10 and FOXD3 were increased in
HCOs, compared with untreated hESCs, after 4 days of treatment with LDN193189 and CHIR99021
(Figure 3B). Expression of the neural crest differentiation marker ZIC1 did not increase, consistent with
the findings of a previous study [35]. At day 28, the formation of HCOs together with enteric neurons
was observed on bright-field microscopy and H&E staining (Figure 3C). The expression of the neuron
differentiation markers TUJ1 and NDRG4 [35] indicated that enteric neurons successfully differentiated
in conjunction with expression of SATB2 in both qRT-PCR and Western blotting (Figure 3C). Positive
immunofluorescent staining for TUJ1 confirmed the successful formation of ENS and HCOs (Figure 3C).
3.3. Development of Colonic Organoids Containing Blood Vessels
Initially, hESCs were differentiated into mesodermal cells by treatment with CHIR99021 for 2 days
(Figure 4A). After CHIR99021 treatment, the expression of OCT4 and NANOG was reduced and
there was an increased expression of the mesoderm differentiation markers EOMES and MIXL1 in
HCOs, compared with untreated hESCs (Figure 4B). These results indicated successful mesoderm
differentiation [28,36]. The vascular promotion stage, induced by treatment with BMP4, VEGF-A,
and FGF4, was observed from day 2 to day 10. The vascular network formation stage, induced by
treatment with SB43154, VEGF-A, and FGF4 from day 10 to 16, was confirmed on immunofluorescent
staining (Figure 4C). Co-culture of blood vessels and hindgut was performed after day 16 by treatment
with BMP4, EGF, CHIR-99021, VEGF-A, and FGF2. Blood vessels were formed with HCOs at day 20
(Figure 4C). The morphology of HCOs containing vessels at different time points was observed on
bright-field microscopy and on H&E staining (day 28). Increased expression of the vascular marker
CD31 [24] and HCO marker SATB2 in HCOs in both qRT-PCR and Western blotting, compared with
untreated hESCs, indicated successful maintenance of the colon and vascular phenotype (Figure 4C).
Successful formation of blood vessels in HCOs was confirmed by immunofluorescent staining of
endothelial cell marker CD31 (Figure 4C).
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Figure 3. Development of HCOs containing ENS. (A) Ectoderm differentiation protocol and the
expression of pluripotency markers (OCT4 and NANOG) and ectoderm differentiation markers
(NESTIN and OTX2) as detected via qRT-PCR. (B) Neural crest differentiation protocol and the
expression of neural crest differentiation markers (ZIC1, SOX10, and FOXD3) as detected via qRT-PCR.
(C) Development of HCOs with ENS development protocol. Morphology of HCO containing ENS at
different time points. Detection of SATB2 and TUJ1 by Western blotting, with GAPDH used as the
loading control. H&E staining of HCO containing ENS, and immunofluorescent staining of of TUJ1.
Expression of neuron differentiation markers (TUJ1 and NDRG4), and colon-specific marker (SATB2)
as detected via qRT-PCR. ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001. n.s. indicates non significance.
The scale bars indicate 200 µm.
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biomarker  testing.  Furthermore,  this  procedure  can  be  applied  for  the  development  of  patient‐
Figure 4. Development of HCOs containing blood vessels. (A) Timeline for development of blood
vessel-containing HCOs. (B) Expression of pluripotency markers (OCT4 and NANOG) and mesoderm
differentiation markers (EOMES and MIXL1) as detected via qRT-PCR. (C) The morphology of blood
vessel structures at days 8, 16, 20, 24, and 28. Immunofluorescent staining of blood vessel endothelial
cell marker (CD31). Detection of SATB2 and CD31 by Western blotting, with GAPDH used as the
loading control. H&E staining of HCO containing blood vessels, and immunofluorescent staining of
CD31. Expression of colon-specific marker (SATB2) and blood vessel endothelial cell marker (CD31) as
detected via qRT-PCR. n.s. indicates non significance. * p ≤ 0.1, ** p ≤ 0.01, and *** p ≤ 0.001. All the
scale bars indicate 200 µm.
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4. Discussion
Our protocol produced HCOs in a reasonably short period of time (28 days). All three germ layer
types (endoderm, mesoderm, and ectoderm) were used to develop the ENS- and blood vessel-containing
HCOs. We confirmed our results with qRT-PCR, Western blotting, and immunofluorescent staining.
After co-culture of the ENS and HCOs, the expression of posterior HOX genes, including HOXA13,
HOXB13, HOXD12, and HOXD13, was elevated in comparison with HCOs. These results were
correlated with the previous study conducted by Múnera et al. [13] and suggested that the colonic
morphology was well maintained after co-culture. However, in this study, hESCs were served as the
original source for the development of colonic organoid; the application of adult stem cells has not
been conducted yet. Further studies should be conducted to optimize the co-culture conditions of ENS,
blood vessels, and colonic organoids derived from adult stem cells or induced pluripotent stem cells.
In addition, cancer organoids also play an important role in elucidating cancer biology, diagnostic,
and prognostic markers [37]. Previous study has shown that cancer organoid models has more resemble
gene expression profiles in vivo in comparison with 2D culture [38,39]. In this study, our group also
successfully applied the current protocol for colon cancer organoids development from colon cancer
cell line SW480. This model can be also served as a source for drug screening and biomarker testing.
Furthermore, this procedure can be applied for the development of patient-derived organoids from
adult stem cells, and facilitates the individualized anticancer drug sensitivity screening with more
accurate prediction outcomes [37].
Additionally, further improvements are needed in which organoids are co-cultured with immune
cells to create colonic organoids that more closely resemble the environment of the human colon.
Recently, microfluidic technology and organoid-on-a-chip platforms have facilitated the development
of multicellular structures with more consistencies in sizes and shapes of organoids [40]. Therefore,
this protocol can also be applied to develop a more complex vessel-colonic organoids with immune cells.
Even though we successfully developed the ENS colonic organoids and vessels colonic organoids
separately, the ENS and vessel-colonic organoids cannot be developed simultaneously. We tried to
co-culture ENS and vessel organoids together but there are no morphological formation of HCOs
containing ENS and vessels (Figure S2). Further study needs to be conducted to optimize the conditions
for develop the more complicated organoids with both ENS and vessels.
5. Conclusions
In the present study, we successfully applied novel techniques for development of well-characterized
enteric nerve and blood vessels in HCOs by 3Dculture. HCOs that contain the enteric nerves and
blood vessels are important for improving our understanding of colon diseases and advancing research
efforts in this area. This is especially true for the study of colon diseases that require the use of a model
that closely resembles the human intestinal environment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/10/2209/s1,
Table S1: Sequences of primers used in this study, Table S2: Primary antibodies used in western blotting and
immunofluorescent staining. Figure S1. Morphology of colon cancer cells (cell line SW480) and development
of colon cancer organoids (CCO). Figure S2. Morphology HCOs using the triple co-culture of HCOs, ENS,
and blood vessels.
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